Wells Fargo & Company Autolus Therapeutics PLC Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Wells Fargo & Company holds 266,315 shares of AUTL stock, worth $551,272. This represents 0.0% of its overall portfolio holdings.
Number of Shares
266,315
Previous 385,873
30.98%
Holding current value
$551,272
Previous $1.4 Million
55.36%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding AUTL
# of Institutions
112Shares Held
156MCall Options Held
0Put Options Held
116K-
Wellington Management Group LLP Boston, MA25.3MShares$52.5 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$42.4 Million0.24% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$34.4 Million73.83% of portfolio
-
Deep Track Capital, LP Greenwich, CT14.2MShares$29.4 Million1.47% of portfolio
-
Avoro Capital Advisors LLC New York, NY9.91MShares$20.5 Million0.34% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $188M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...